419 related articles for article (PubMed ID: 7684435)
1. CD28-B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help.
Harding FA; Allison JP
J Exp Med; 1993 Jun; 177(6):1791-6. PubMed ID: 7684435
[TBL] [Abstract][Full Text] [Related]
2. CD28 interaction with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting T lymphocytes.
Azuma M; Cayabyab M; Buck D; Phillips JH; Lanier LL
J Exp Med; 1992 Feb; 175(2):353-60. PubMed ID: 1370679
[TBL] [Abstract][Full Text] [Related]
3. CD28 ligation by monoclonal antibodies or B7/BB1 provides an accessory signal for the cyclosporin A-resistant generation of cytotoxic T cell activity.
Van Gool SW; de Boer M; Ceuppens JL
J Immunol; 1993 Apr; 150(8 Pt 1):3254-63. PubMed ID: 7682237
[TBL] [Abstract][Full Text] [Related]
4. Involvement of altered B7 expression in dioxin immunotoxicity: B7 transfection restores the CTL but not the autoantibody response to the P815 mastocytoma.
Prell RA; Kerkvliet NI
J Immunol; 1997 Mar; 158(6):2695-703. PubMed ID: 9058803
[TBL] [Abstract][Full Text] [Related]
5. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1.
Tan P; Anasetti C; Hansen JA; Melrose J; Brunvand M; Bradshaw J; Ledbetter JA; Linsley PS
J Exp Med; 1993 Jan; 177(1):165-73. PubMed ID: 7678111
[TBL] [Abstract][Full Text] [Related]
6. Requirements for CD28-dependent T cell-mediated cytotoxicity.
Azuma M; Cayabyab M; Phillips JH; Lanier LL
J Immunol; 1993 Mar; 150(6):2091-101. PubMed ID: 8383716
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of B7-1 and B7-2 on the costimulation of mouse nonspecific cytotoxic T lymphocyte development in response to anti-CD3 antibody.
Makrigiannis AP; Musgrave BL; Hoskin DW
J Leukoc Biol; 1999 Nov; 66(5):792-802. PubMed ID: 10577511
[TBL] [Abstract][Full Text] [Related]
8. Costimulation via vascular cell adhesion molecule-1 induces in T cells increased responsiveness to the CD28 counter-receptor B7.
Damle NK; Klussman K; Leytze G; Ochs HD; Aruffo A; Linsley PS; Ledbetter JA
Cell Immunol; 1993 Apr; 148(1):144-56. PubMed ID: 7684325
[TBL] [Abstract][Full Text] [Related]
9. CD2/LFA-3 or LFA-1/ICAM-1 but not CD28/B7 interactions can augment cytotoxicity by virus-specific CD8+ cytotoxic T lymphocytes.
de Waal Malefyt R; Verma S; Bejarano MT; Ranes-Goldberg M; Hill M; Spits H
Eur J Immunol; 1993 Feb; 23(2):418-24. PubMed ID: 7679643
[TBL] [Abstract][Full Text] [Related]
10. B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro.
Gajewski TF
J Immunol; 1996 Jan; 156(2):465-72. PubMed ID: 8543795
[TBL] [Abstract][Full Text] [Related]
11. CD4 help-independent induction of cytotoxic CD8 cells to allogeneic P815 tumor cells is absolutely dependent on costimulation.
Zhan Y; Corbett AJ; Brady JL; Sutherland RM; Lew AM
J Immunol; 2000 Oct; 165(7):3612-9. PubMed ID: 11034363
[TBL] [Abstract][Full Text] [Related]
12. Differential T cell costimulatory requirements in CD28-deficient mice.
Shahinian A; Pfeffer K; Lee KP; Kündig TM; Kishihara K; Wakeham A; Kawai K; Ohashi PS; Thompson CB; Mak TW
Science; 1993 Jul; 261(5121):609-12. PubMed ID: 7688139
[TBL] [Abstract][Full Text] [Related]
13. Either B7 costimulation or IL-2 can elicit generation of primary alloreactive CTL.
McAdam AJ; Gewurz BE; Farkash EA; Sharpe AH
J Immunol; 2000 Sep; 165(6):3088-93. PubMed ID: 10975820
[TBL] [Abstract][Full Text] [Related]
14. Accessory signalling by B7-1 for T cell activation induced by anti-CD2: evidence for IL-2-independent CTL generation and CsA-resistant cytokine production.
Van Gool SW; Kasran A; Wallays G; de Boer M; Ceuppens JL
Scand J Immunol; 1995 Jan; 41(1):23-30. PubMed ID: 7529939
[TBL] [Abstract][Full Text] [Related]
15. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4.
Chen L; Ashe S; Brady WA; Hellström I; Hellström KE; Ledbetter JA; McGowan P; Linsley PS
Cell; 1992 Dec; 71(7):1093-102. PubMed ID: 1335364
[TBL] [Abstract][Full Text] [Related]
16. Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma.
Li Y; McGowan P; Hellström I; Hellström KE; Chen L
J Immunol; 1994 Jul; 153(1):421-8. PubMed ID: 7515929
[TBL] [Abstract][Full Text] [Related]
17. Increased cytolytic T lymphocyte activity and decreased B7 responsiveness are associated with CD28 down-regulation on CD8+ T cells from HIV-infected subjects.
Vingerhoets JH; Vanham GL; Kestens LL; Penne GG; Colebunders RL; Vandenbruaene MJ; Goeman J; Gigase PL; De Boer M; Ceuppens JL
Clin Exp Immunol; 1995 Jun; 100(3):425-33. PubMed ID: 7539725
[TBL] [Abstract][Full Text] [Related]
18. The capacity of the natural ligands for CD28 to drive IL-4 expression in naïve and antigen-primed CD4+ and CD8+ T cells.
Bian Y; Hiraoka S; Tomura M; Zhou XY; Yashiro-Ohtani Y; Mori Y; Shimizu J; Ono S; Dunussi-Joannopoulos K; Wolf S; Fujiwara H
Int Immunol; 2005 Jan; 17(1):73-83. PubMed ID: 15569772
[TBL] [Abstract][Full Text] [Related]
19. Functional expression of B7/BB1 on activated T lymphocytes.
Azuma M; Yssel H; Phillips JH; Spits H; Lanier LL
J Exp Med; 1993 Mar; 177(3):845-50. PubMed ID: 7679711
[TBL] [Abstract][Full Text] [Related]
20. B7-CD28 costimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes.
Johnston JV; Malacko AR; Mizuno MT; McGowan P; Hellström I; Hellström KE; Marquardt H; Chen L
J Exp Med; 1996 Mar; 183(3):791-800. PubMed ID: 8642283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
